Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2017

Open Access 01-12-2017 | Research article

Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study

Authors: Colman Siu Cheung Fung, Eric Yuk Fai Wan, Anca Ka Chun Chan, Cindy Lo Kuen Lam

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Login to get access

Abstract

Background

The benefit of statin on the management of Type 2 Diabetes Mellitus (T2DM) among Chinese patients in primary care is not clear nor fully implemented in clinical practice. This study aimed to evaluate and quantify the benefit of statin on the overall cardiovascular risk and all-cause mortality in patients with T2DM.

Methods

Uncomplicated diabetic patients with baseline low-density-lipoprotein cholesterol (LDL-C) > 2.6 mmol/L and without statin use before baseline in 2010 were followed-up for 5 years for cardiovascular disease (CVD) events and all-cause mortality. Propensity score matching analysis was conducted to identify patients who were newly prescribed statin at baseline and then compared to non-statin users with similar baseline characteristics. Subgroup analysis was done within the statin group to detect any difference in outcomes between patients achieving target LDL-C of <2.6 mmol/L and not. Multivariable Cox proportional hazards regression with adjustment of all baseline covariates was used to evaluate the effect of statin on outcome events. Hazard ratio (HR) and its 95% confidence intervals were reported.

Results

10,104 pairs of diabetic patients were propensity score matched. Statin users had an extra drop of 1.21 mmol/L in LDL-C than non-users. Statin group had a CVD incidence rate of 16.533 per 1000 person-years whereas comparison group had 32.387 per 1000 person-years (HR: 0.458) during a median follow-up period of 50.5 months. Statin group had a mortality rate of 8.138 deaths per 1000 person-years whereas comparison group had 19.603 deaths per 1000 person-years (HR: 0.378). For patients prescribed with statin, the HR was 0.491 for CVD and 0.487 for all-cause mortality if target of LDL-C < 2.6 mmol/L achieved compare to those not achieved.

Conclusions

Use of statin was associated with a significant decrease in CVD risk and all-cause mortality among diabetic patients in primary care, and the risk reduction was most significant if the target of LDL-C less than 2.6 mmol/L was achieved.
Literature
1.
go back to reference Brugts J, Yetgin T, Hoeks S, Gotto A, Shepherd J, Westendorp R, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.CrossRefPubMedPubMedCentral Brugts J, Yetgin T, Hoeks S, Gotto A, Shepherd J, Westendorp R, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.CrossRefPubMedPubMedCentral
2.
go back to reference Fung CS, Chin WY, Dai DS, Kwok RL, Tsui EL, Wan YF, et al. Evaluation of the quality of care of a multi-disciplinary risk factor assessment and management programme (RAMP) for diabetic patients. BMC Fam Pract. 2012;13(1):116.CrossRefPubMedPubMedCentral Fung CS, Chin WY, Dai DS, Kwok RL, Tsui EL, Wan YF, et al. Evaluation of the quality of care of a multi-disciplinary risk factor assessment and management programme (RAMP) for diabetic patients. BMC Fam Pract. 2012;13(1):116.CrossRefPubMedPubMedCentral
3.
go back to reference Ulm K. Simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131(2):373–5.CrossRefPubMed Ulm K. Simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131(2):373–5.CrossRefPubMed
4.
go back to reference Trialists CT. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.CrossRef Trialists CT. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.CrossRef
5.
go back to reference Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.CrossRefPubMed Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.CrossRefPubMed
6.
go back to reference Libby P, Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol. 2003;26(S1):11–4.CrossRef Libby P, Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol. 2003;26(S1):11–4.CrossRef
7.
go back to reference Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):Iii39–43. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):Iii39–43.
8.
go back to reference Zimmerman MP. How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control? American health & drug benefits. 2015;8(8):436. Zimmerman MP. How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control? American health & drug benefits. 2015;8(8):436.
9.
go back to reference Chan JC, Chan SP, Deerochanawong C, Go RT, Lee K-O, Ma RC-W, et al. Diabetic dyslipidaemia in Asian populations in the Western Pacific region: what we know and don’t know. Diabetes Res Clin Pract. 2011;94(1):1–13.CrossRefPubMed Chan JC, Chan SP, Deerochanawong C, Go RT, Lee K-O, Ma RC-W, et al. Diabetic dyslipidaemia in Asian populations in the Western Pacific region: what we know and don’t know. Diabetes Res Clin Pract. 2011;94(1):1–13.CrossRefPubMed
11.
go back to reference Lin JS. An alternative treatment of hyperlipidemia with red yeast rice: a case report. J Med Case Rep. 2010;4(1):1.CrossRef Lin JS. An alternative treatment of hyperlipidemia with red yeast rice: a case report. J Med Case Rep. 2010;4(1):1.CrossRef
12.
go back to reference Xie W, Zhao Y, Du L. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol. 2012;140(2):345–67.CrossRefPubMed Xie W, Zhao Y, Du L. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol. 2012;140(2):345–67.CrossRefPubMed
13.
go back to reference Collins R, Reith C, Emberson J, Armitage J, Baigent C. Blackwell L, et al. The Lancet: Interpretation of the evidence for the efficacy and safety of statin therapy; 2016. Collins R, Reith C, Emberson J, Armitage J, Baigent C. Blackwell L, et al. The Lancet: Interpretation of the evidence for the efficacy and safety of statin therapy; 2016.
14.
go back to reference Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34(10):1637–59.PubMed Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34(10):1637–59.PubMed
15.
go back to reference Ting RZ, Yang X, Yu LW, Luk AO, Kong AP, Tong PC, et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol. 2010;9:77.CrossRefPubMedPubMedCentral Ting RZ, Yang X, Yu LW, Luk AO, Kong AP, Tong PC, et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol. 2010;9:77.CrossRefPubMedPubMedCentral
16.
go back to reference Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998;316(7134):823–8.CrossRefPubMedPubMedCentral Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998;316(7134):823–8.CrossRefPubMedPubMedCentral
17.
go back to reference Trialists CT. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25.CrossRef Trialists CT. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25.CrossRef
18.
go back to reference Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias. European heart journal. 2016:ehw272. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias. European heart journal. 2016:ehw272.
19.
go back to reference American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(Suppl 1):S1–S93. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(Suppl 1):S1–S93.
Metadata
Title
Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study
Authors
Colman Siu Cheung Fung
Eric Yuk Fai Wan
Anca Ka Chun Chan
Cindy Lo Kuen Lam
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0599-x

Other articles of this Issue 1/2017

BMC Cardiovascular Disorders 1/2017 Go to the issue